Integer Agrees to Be Taken Private by KKR in $5.7 Billion Deal

Integer Holdings agreed to be taken private by KKR in a $5.7 billion deal, with KKR to buy the company for about $4.3 billion, according to reports. The article also notes Truist Securities downgraded Integer to Hold from Buy and raised its price target to $127 from $110.

Original reporting
Published Aug 3, 2026, 1:29 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 5:46 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefMergers & acquisitions
Primary signal
$ITGR
Bullish
medium confidence
Mentioned
$ITGR
Relevance
9/10
alphai data visualization · based on marketscreener.com
Decision brief

The 30-second read

$ITGRBullishHigh
01

Why it matters

A take-private agreement typically shifts the stock’s valuation framework from standalone fundamentals to deal completion probability and implied offer economics, increasing sensitivity to deal-condition headlines.

02

Market read

Traders can act on deal-announcement dynamics, including potential spread/arb positioning and monitoring of deal-condition updates.

03

What to watch

The body also mentions a same-day analyst downgrade and price-target change, which can affect near-term trading even if the deal dominates longer-term valuation.

Relevance 9/10Novelty 9/10Timing: deal announcement reported pre-market today

Background

The text indicates Integer Holdings is the target of a KKR take-private transaction, with deal value cited and an analyst downgrade/PT update also referenced.

Company-level read

Ticker impact

$ITGRBullishMedium confidence
Context

Integer Holdings agreed to be taken private by KKR in a $5.7 billion deal, making the transaction a direct catalyst for ITGR risk and valuation.

Expected impact

Expect volatility around deal terms and any subsequent updates, with downside risk if deal conditions deteriorate.

Evidence & confidence

The article’s newest concrete fact is the KKR buyout agreement and deal size, which typically moves the target stock toward the implied offer value and then trades on deal progress.

Market effects

Could modestly lift sentiment for deal activity in the industrials/services space, but the article is single-company focused.

Primarily US-listed single-name impact; limited regional spillover implied.

KKR involvement may attract broader buyout attention, but no other global counterparties are detailed.

Counterpoint

Deal-premium trades can unwind quickly if financing, regulatory, or shareholder-approval hurdles emerge, so the initial pop may not persist.

Key entities

  • Integer Holdings

    Subject of the take-private agreement with KKR, with deal value cited in the article.

  • KKR

    Buyer in the announced $5.7 billion take-private deal for Integer Holdings.

Related articles

$ITGRHighAI 9/10

What Integer's Deal Means for Minnesota's Med Device Industry

Integer Holdings, a major medical device manufacturer, is being acquired by KKR for $5.7B. Integer supplies components to companies like Abbott, Boston Scientific, and Medtronic. The deal may impact Minnesota's med-tech industry, where Integer has significant operations. KKR's acquisition could lead to consolidation in the sector, with potential implications for competition and pricing. Integer reported $1.8B in revenue last year.

$KKRHighAI 9/10

KKR to Acquire Integer Holdings in $5.7 Bn All-Cash Deal

KKR will acquire medical device outsourcing company Integer Holdings in an all-cash deal valued at about $5.7 billion, paying $127 per share and assuming Integer’s outstanding debt, according to the companies. The offer implies a 4.78% premium to Integer’s Friday close. Integer shares rose 2.4% premarket. KKR said it will expand its healthcare portfolio.

$SUPNMed

Biotech funding rises 75% year-over-year, Braveheart surges

Macquarie said global biotech funding for the year through Aug. 7 rose 75% YoY, driven by IPOs up 235% and follow-ons up 138%. The XBI biotech index gained 7% in the week to Aug. 7. Braveheart Bio’s upsized IPO raised $382.5M and shares jumped 66%. Curium agreed to buy Lantheus for up to $8B, and Supernus and Indivior plan an all-stock merger.

$KKRHighAI 9/10

KKR to take Integer private for $5.7B

KKR agreed to buy Integer Holdings for about $5.7B in an all-cash deal, taking Integer private. The transaction is expected to close before year-end, subject to regulatory approvals and shareholder support. Integer stockholders would receive about $127 per share, a 51%+ premium to April 29. Integer reported $464M Q2 sales, down 2.6%.